Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + ddAC in HER2- Breast Cancer
NCT02790580Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in breast cancer (2 arms), sponsored by National University Hospital. Primary endpoint: Clinical response rate. Status: unknown.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02790580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790580.